Expert Interview
Discussing the potential of mRNA-4157, a personalized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor, pembrolizumab, for patients with high-risk melanoma
Ticker(s): MRK, MRNAInstitution: South Nassau Oncology
- Senior Partner of South Nassau Oncology, Professor of Medicine at the Mount Sinai Hospital and Former Director of the Cancer Program at the Mount Sinai Hospital
- Clinical focus on hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma and leukemias; as well as cancers of the lung, colon and breast.
- treats 90 patients with HR+/HER2- metastatic breast cancer
- Very familiar with the Phase 3 results from the TROPiCS-02 study presented at ESMO- attended in person
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
